DEBN is a medical device company focused on developing a novel prostate biopsy needle for urologists. The needle delivers an optimal combination of antibiotics directly to the prostate, targeting the source of potential infections. By using this method, DEBN's needle allows for the use of more effective antibiotics that are not suitable for oral prophylaxis. The device consists of a polymer-coated biopsy and anesthesia needle that release drugs during the procedure, reducing the risk of infections and broadening the spectrum of antibiotic activity. This innovation has the potential to save $2B in the cost of treating infections following 5M biopsies worldwide.